Medisafe 1 to launch syringe locking device in Jerusalem hospital

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company has engaged in preliminary discussions to launch a pilot of its syringe locking device, with a major hospital in Jerusalem.

The discussions are focusing on implementing the technology in one of the hospital's internal departments. The target date for launching the pilot program is within the next six months.

The pilot will demonstrate the effectiveness of the device to physically block the administration of incorrect medications or dosages to patients in the department.

The technology features a barcode reader that confirms both the medication and its intended patient. If the system does not verify the correct dosage and patient, the locking device on the syringe will not open and enable administration.

"We are optimistic about the early discussions with a very well-respected department in one of the region's best hospitals," said Jacob Elhadad, CEO of Medisafe 1 Technologies. "The successful implementation of this pilot could potentially lead to more widespread demand for our technology."

"The number of deaths caused around the world by the human error in the administration of improper medicines or dosages in hospitals is staggering. The cost of human life, and the cost of medical malpractice suits far outweigh the costs of implementing better technology," Elhadad added.